Previous 10 | Next 10 |
Study finds no in-vitro pharmacological difference in the antiproliferative, anti-inflammatory, or permeability effects of purified natural versus synthetic CBD Study further validates Artelo’s strategy to develop a synthetic CBD-cocrystal with enhanced pharmaceutical pro...
LA JOLLA, Calif., July 21, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced th...
Artelo Biosciences (ARTL): Q3 GAAP EPS of -$0.10 misses by $0.02.As of May 31, 2021, the Company had approximately $10,052,288 in cash and cash equivalents.Press Release For further details see: Artelo Biosciences EPS misses by $0.02
Enrollment in CAReS Study in patients with cancer anorexia on track to deliver first data readout by calendar year-end $10.0 Million of Cash and Cash Equivalents as of May 31, 2021 SOLANA BEACH, Calif., July 12, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASD...
Exciting opportunities are emerging for new therapies that target the recently identified endocannabinoid system, which governs numerous cellular processes in human body. To economically build portfolio value, Artelo’s business model relies on both in-licensed and internally de...
LA JOLLA, Calif., July 07, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, today announced th...
Dr. Andrew Yates to Present Poster on the Company’s ART27.13 Cancer Appetite Recovery Study Prof. Saoirse O’Sullivan to Present Poster Related to Artelo’s ART12.11 CBD Cocrystal and the Effects of CBD and TMP Coadministration in Cancer LA JOLLA, Calif....
LA JOLLA, Calif., June 02, 2021 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today annou...
La Jolla, California--(Newsfile Corp. - May 6, 2021) - Artelo Biosciences, Inc. (NASDAQ: ARTL ) , a clinical stage biopharmaceutical company focused on the development of therapeutics that target lipid-signaling pathways, including the endocannabinoid system, today announced that Gregory...
Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors PR Newswire SAN DIEGO , May 4, 2021 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid t...
News, Short Squeeze, Breakout and More Instantly...
Artelo Biosciences Inc. Company Name:
ARTL Stock Symbol:
OTCMKTS Market:
Artelo Biosciences Inc. Website:
ART26.12 seeks to address a critical need in painful neuropathies, including chemotherapy-induced peripheral neuropathy for which there is no FDA-approved treatment Phase 1 trial results expected in the first half of 2025 SOLANA BEACH, Calif., July 15, 2024 (GLOBE NEWSWIRE) -- A...
SOLANA BEACH, Calif., July 03, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatologic and neurological condit...
Inhibition of FABP5 Demonstrates Activity in Cancer, Psoriasis, and Anxiety Disorders Results from Several Research Studies Presented at the Annual ICRS Symposium SOLANA BEACH, Calif., July 02, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL) , a c...